Second-line therapy for gemcitabine-refractory pancreatic cancer: Is there a standard?

ONCOLOGY

Volumn 22, Issue 10, 2008, Pages 1176-1183

  Almhanna, Khaldoun ^a   Kim, Richard ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ARSENIC TRIOXIDE; CAMPTOTHECIN; CAPECITABINE; CELECOXIB; CISPLATIN; CISPLATIN DERIVATIVE; DOCETAXEL; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LIPOPLATIN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PERIFOSINE; RALTITREXED; RUBITECAN; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ANTICHOLINERGIC SYNDROME; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPOCALCEMIA; INFECTION; LETHARGY; LEUKOPENIA; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT CARE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PUBLICATION; REVIEW; SAMPLE SIZE; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 54949112461     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997.
3. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960-1966, 2007.
4. Cunningham, D, Chau I, Stocken D, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer (abstract PS11). Eur J Cancer 3:4, 2005.
5. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the central European cooperative oncology group. J Clin Oncol 25:2212-2217, 2007.
6. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007.
7. Oettle H, Pelzer U, Stieler J, et al: Oxaliplatin/folinic acid/ 5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003) (abstract 4031). J Clin Oncol 23(16S):315s, 2005.
8. Heinemann V, Hinke A, Boeck S, et al: Gemcitabine-based combinations (gem+x) vs. gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: A meta- analysis of sixteen randomized trials (abstract 4515). J Clin Oncol 25(18S):201s, 2007.
9. Xiong HQ, Wolff RA, Hess KR, et al: A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer (abstract 4119). J Clin Oncol 24(18S):207s, 2006.
10. Pelzer U, Hempel C, Stieler J, et al: Oxaliplatin (OXA) in combination with high dose 5-FU (24h)/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer (abstract 684). Proc Am Soc Clin Oncol 21, 2002.
11. Tsavaris N, Kosmas C, Skopelitis H, et al: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 23:369-375, 2005.
12. Reni M, Pasetto L, Aprile G, et al: Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 94:785-791, 2006.
13. Demols A, Peeters M, Polus M, et al: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer 94:481-485, 2006.
14. Tschoep KE, Milani V, Schmidt G, et al: Gemcitabine + cisplatin (GEM+CIS) in combination with regional hyperthermia (RHT) in second-line therapy of gemcitabine-refractory metastatic pancreatic cancer (abstract 14073). J Clin Oncol 24(18S):629s, 2006.
15. Stathopoulos GP, Boulikas T, Vougiouka M, et al: Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study. Oncol Rep 15:1201-1204, 2006.
16. Riess H, Pelzer U, Stieler J, et al: A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003 (abstract 4517). J Clin Oncol 25(18S):201s, 2007.
17. Cartwright TH, Cohn A, Varkey JA, et al: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160-164, 2002.
18. Blaya M, Lopes GD, Roman E, et al. Phase II trial of capecitabine and docetaxel for locally advanced and metastatic pancreatic cancer previously treated with gemcitabine based therapy (abstract 15029). J Clin Oncol 25(18S):636s, 2007.
19. Lopes G, Bastos B, Ahn E, et al: A phase II trial of capecitabine and docetaxel in patients with previously treated pancreatic cancer (abstract 14111). J Clin Oncol 24(18S):633s, 2006.
20. Fogelman DR, Schreibman S, Fine RL: Effective salvage therapy (T-GX) for pancreatic cancer patients after treatment with GTX (abstract 4268). Proc Am Soc Clin Oncol 23:379, 2004.
21. Gelibter A, Milella M, Malaguti P, et al: Pilot study of capecitabine combined with celecoxib (CapCel) as second-line treatment for advanced pancreatic (P) and biliary tree (BT) cancer (abstract 14055). J Clin Oncol 24(18S):628s, 2006.
22. Kulke MH, Blaszkowsky LS, Ryan DP, et al: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792, 2007.
23. Park Y, Yi S, Kim H, et al: Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer (abstract 15111). J Clin Oncol 25(18S):642s, 2007.
24. Burris HA, Rivkin S, Reynolds R, et al: Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 10:183-190, 2005.
25. Jacobs AD, Burris HA, Rivkin S, et al: A randomized phase III study of rubitecan (ORA) vs best choice (BC) in 409 patients with refractory pancreatic cancer report from a north-american multi-center study (abstract 4013). Proc Am Soc Clin Oncol 23:315, 2004.
26. Ulrich-Pur H, Raderer M, Verena Kornek G, et al: Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88:1180-1184, 2003.
27. Ng M, Norman AR, Cunningham D, et al: Phase II trial evaluating a 2 weekly regimen of irinotecan (IR) and 5-FU/leucovorin (LV) in patients with metastatic pancreatic cancer refractory to chemotherapy (abstract 4229). Proc Am Soc Clin Oncol 23:369, 2004.
28. Reni M, Panucci MG, Passoni P, et al: Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: A phase I and II trial. Cancer Invest 22:688-696, 2004.
29. Kozuch P, Grossbard ML, Barzdins A, et at: Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatun (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6:488-495, 2001.
30. Oettle H, Arnold D, Esser M, et al: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11:635-638, 2000.
31. Blaszkowsky LS, Ryan DP, Earle C, et al: A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer (abstract 15080). J Clin Oncol 25(18S):640s, 2007.
32. Ignatiadis M, Polyzos A, Stathopoulos GP, et al: A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 71:159-163, 2006.
33. Boeck S. Weigang-Kohler K, Fuchs M, et al: Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial. Ann Oncol 18:745-751, 2007.
34. Blaszkowsky LS, Kulke KH, Ryan DP, et al: A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer (abstract 4099). J Clin Oncol 23(16S):332s, 2005.
35. Schuetz T, Kaufman HL, Marshall JL, et al: Extended survival in second-line pancreatic cancer after therapeutic vaccination (abstract 2576). J Clin Oncol 23(16S):184s, 2005.
36. Sharma JJ, Razvillas B, Stephens CD, et al: Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 15:361-364, 1997.
37. Aklilu M, Kindler HL, Nattam S, et al: A multi-center phase II study of arsenic trioxide (AT) in patients (pts) with advanced pancreatic cancer (PC) refractory to gemcitabine (abstract 4114). Proc Am Soc Clin Oncol 23:340, 2004.
38. Regine WF, Winter KW, Abrams R, et al: RTOG 9704: A phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma (abstract 4007). J Clin Oncol 24(18S):180s, 2006.
39. Klapdor R, Bahlo M, Babinsky A, et al: Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer. Anticancer Res 27(4A):1789-1794, 2007.
40. Nakachi K, Furuse J, Ishii H, et al: Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37:114-120, 2007.
41. Mancuso A, Sacchetta S, Saletti P, et al: Clinical and molecular determinants of survival in pancreatic cancer patients treated with second line chemotherapy: Results of an Italian/Swiss multicenter survey (abstract 4622). J Clin Oncol 25(18S):228s, 2007.
42. Javle MM, Okazaki T, Wolff R, et al: Combined effect of single nucleotide polymorphisms (SNPs) of gemcitabine metabolic genes on pancreatic cancer survival and drug toxicity (abstract 126). Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, Fla, Jan 25-27, 2008.
43. Morizane T. Okusaka J, Furuse H, et al: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer (abstract 4115). J Clin Oncol 24(18S):206s, 2006.
44. Hedley D, Moore MJ, Hirte H, L, et al: A phase II trial of perifosine as second line therapy for advanced pancreatic cancer (abstract 4166). J Clin Oncol 23(16S):349s, 2005.
45. Milella M, Gelibter A, Di Cosimo S, et al: Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101:133-138, 2004.
46. Cantore M, Rabbi C, Fiorentini G, et al: Combined irinotecan and oxaliptatin in patients with advanced pre-treated pancreatic cancer. Oncology 67:93-97, 2004.